LLY

918.96

+0.38%↑

JNJ

238.2

+0.37%↑

ABBV

206.76

-1.17%↓

NVS

147.4

-2.27%↓

AZN

187.84

-0.85%↓

LLY

918.96

+0.38%↑

JNJ

238.2

+0.37%↑

ABBV

206.76

-1.17%↓

NVS

147.4

-2.27%↓

AZN

187.84

-0.85%↓

LLY

918.96

+0.38%↑

JNJ

238.2

+0.37%↑

ABBV

206.76

-1.17%↓

NVS

147.4

-2.27%↓

AZN

187.84

-0.85%↓

LLY

918.96

+0.38%↑

JNJ

238.2

+0.37%↑

ABBV

206.76

-1.17%↓

NVS

147.4

-2.27%↓

AZN

187.84

-0.85%↓

LLY

918.96

+0.38%↑

JNJ

238.2

+0.37%↑

ABBV

206.76

-1.17%↓

NVS

147.4

-2.27%↓

AZN

187.84

-0.85%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

29.18 1.71

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.76

Max

29.21

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+85.22% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	394M 2B
Ankstesnė atidarymo kaina	27.47
Ankstesnė uždarymo kaina	29.18

Naujienos nuotaikos

By Acuity

50%

171 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-18 22:51; UTC

Uždarbis

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

2026-03-18 21:40; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

2026-03-18 20:31; UTC

Uždarbis

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

2026-03-18 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

2026-03-18 23:31; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery -- Market Talk

2026-03-18 22:49; UTC

Rinkos pokalbiai

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

2026-03-18 22:41; UTC

Rinkos pokalbiai

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

2026-03-18 22:36; UTC

Uždarbis

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

2026-03-18 22:24; UTC

Uždarbis

AIA Group Announces New Share Buyback of $1.7B >1299.HK

2026-03-18 22:23; UTC

Uždarbis

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

2026-03-18 22:23; UTC

Uždarbis

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

2026-03-18 21:58; UTC

Uždarbis

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

2026-03-18 21:55; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-03-18 21:55; UTC

Rinkos pokalbiai

Uždarbis

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

2026-03-18 21:40; UTC

Rinkos pokalbiai

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

2026-03-18 21:16; UTC

Rinkos pokalbiai

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

2026-03-18 21:00; UTC

Svarbiausios naujienos

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

2026-03-18 20:58; UTC

Uždarbis

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

2026-03-18 20:41; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:29; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:25; UTC

Uždarbis

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026-03-18 20:17; UTC

Uždarbis

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

2026-03-18 20:14; UTC

Rinkos pokalbiai

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

2026-03-18 20:09; UTC

Uždarbis

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

2026-03-18 20:07; UTC

Uždarbis

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

2026-03-18 20:06; UTC

Uždarbis

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

2026-03-18 20:04; UTC

Uždarbis

Micron Technology Sees 3Q Gross Margin About 81% >MU

2026-03-18 20:03; UTC

Uždarbis

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

85.22% į viršų

12 mėnesių prognozė

Vidutinis 54.9 USD 85.22%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

171 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.